Alimera Sciences Inc (NASDAQ:ALIM) Cheers on First-Quarter Results- ALIM, PFE, MRK, KERX, BMY, SNY, LLY

Alimera Sciences Inc (NASDAQ:ALIM) moved up 3.76 percent to $2.76 following the firm reported Q1 results.  Research and development expenses were $1.6 million evaluated to $1.8 million in the Q1 of 2011. Net loss was $4.4 million or $0.14 a share evaluated to net loss of $4.7 million or $0.15 a share in the previous year quarter. Cash, cash equivalents and investments was $27.6 million as on March 31, 2011.

The firm plans to meet with the FDA toward the end of the Q2 of 2012 to discuss the FDA’s November 2011 total response letter regarding Alimera’s New Drug Application for ILUVIEN for the treatment of Diabetic Macular Edema.

Turning towards the investors who viewing ALIM against Pfizer Inc. (NYSE:PFE) small declined -0.79%, Merck & Co., Inc. (NYSE:MRK) lost -0.94%, Keryx Biopharmaceuticals (NASDAQ:KERX) rose +15.24%, Bristol Myers Squibb Co. (NYSE:BMY) slipped -0.24%, Sanofi SA (ADR) (NYSE:SNY) which also increased +0.36% and Eli Lilly & Co. (NYSE:LLY) traded at flat.

Alimera Sciences Inc (NASDAQ:ALIM) stock reports on May 11, 2012 increased 1.50% to the closing price of $2.70. Its fifty two week range was $1.09-$9.07. The total market capitalization remained $84.85 billion.

The overall volume in the last trading session was 66,450.00 shares. In its share capital ALIM has 31.43 million outstanding shares among them 15.07 million shares have been floated in market exchange. ALIM stock institutional ownership remained 81.90% while insider ownership included 74.39%.

ALIM is ahead its 52 week low with 147.71% and lagging behind from its 52 week high price with -70.23%. ALIM last month stock price volatility remained 7.88%. The stock price of ALIM is moving down from its 20 days moving average with -7.99% and remote negatively from 50 days moving average with -20.03%.

ALIM current year earnings per share experienced an addition with 24.08% while its current quarter performance remained -63.64%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.